Corporate Info

Orion Genomics develops oncology diagnostic products for cancer screening and therapy selection. We leverage our suite of proprietary technologies to find and interpret normal and abnormal epigenetic patterns of DNA methylation, also known as DNA's Second Code.

We are currently identifying epigenetic biomarkers and employing them in the development of novel molecular diagnostic tests to find breast, lung, ovarian, colorectal and other common cancers. Additionally, we are discovering biomarkers that can aid in the selection of best therapies for cancer patients.